April 2026 - Corcept Therapeutics

Real-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)

April 13, 2026

Coleman et al. • 2026 • SGO

Relacorilant Plus Nab-Paclitaxel Demonstrates a Progression-Free Survival Benefit in Ovarian Cancer Independent of Tumor Glucocorticoid Receptor (GR) Expression Levels

April 13, 2026

Lorusso et al. • 2026 • SGO

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

April 13, 2026

Lorusso et al. • 2026 • SGO

Final Overall Survival Results from the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)

April 10, 2026

Lorusso et al. • The Lancet • Olawaiye et al. • SGO • 2026